Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    "hereditary leiomyomatosis and renal cell cancer"
Show Display Options
Download search resultsDownload the search results for:
"hereditary leiomyomatosis and renal cell cancer" (3 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
2 Completed
Has Results
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Conditions: Cutaneous Leiomyomas;   Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions: Biological: Botulinum toxin type A;   Other: Placebo
3 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin

Study has passed its completion date and status has not been verified in more than two years.